Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's all, eh?
Good to hear.
University research thirsts from research dollars provided by the government. The government likes to hand out these dollars and report that it is making scientific advancements.
Whether these are actually fruitful or productive is another question. Fruitful and productive ventures are almost always scooped up by the private sector. Just because an academic is willing to research an interesting compound using government money and then gets to present it, does not mean that the compound is viable in the market.
This company was geared up to go to NASDAQ, partnership and phase 3 with this very same compound and delivery method (Brilacidin IV) in 2015 on the heels of a successful phase 2B antibiotic trial. Why will it be different this time in 2022 with much lower means and on the heels of a phase 2 anti-viral trial failure?
Because some university professor is hyped about it?
DeGrado was hot on this thing for two decades. Academic interest does not translate into market interest.
The years continue to go by and the IPIX pipeline regresses each year. We had a billion dollar antibiotic just about ready for phase 3 in 2015. Now you're excited about a poster presentation outlining preclinical data for an indication that failed a phase 2 trial...
I can't help but notice Amgen never went from $4.60 to $0.03 and never had <10 employees.
It's almost like Amgen was a legitimate pharma company that built value over time with consistent results and a steady mission.
Ours looks a lot more like this one in terms of chart and mission:
https://www.bing.com/search?q=NNVC&qs=n&form=QBRE&sp=-1&pq=nnvc&sc=10-4&sk=&cvid=35BD2CFF72D444BFB94D3E28AC512B34&ghsh=0&ghacc=0&ghpl=
You know...constantly changing direction while losing 99% of shareholder value while the CEO gets bankrolled.
Please....bring a sweet merciful end to this debacle of an investment.
Be wary of "valuable information" on this board. It has never panned out in the seven years I have been here.
There have been countless claims of scoop on trial results, deal making, etc. All bunk. It's no surprise when you can barely trust the 10Qs around here.
When was the last time your government bought a pharmaceutical company?
It's a strong synonym of "soon" or "just around the corner".
As in Brilacidin deals "just around the corner in 2016."
I just hope it's more profitable than our last $5M investment.
Yes. I asked around to many offering to sell my shares for $1.00 stating they are worth a minimum of $1.50. I haven't found any takers yet.
Too bad we can't convince anyone not holding IPIX shares of that.
He was going to sell all his shares in November days ahead of failed COVID trial results?
First off he probably couldn't at pretty much any time during the COVID trial. You don't risk those optics and possible SEC action when you're coasting making $500K/year with the possibility that the drug works. And you definitely don't do it when you have locked in $10M to keep that salary going for 20 years if you know the drug doesn't work.
The key to a successful OTC operation is don't get too greedy. He has a great thing going right now. If the drugs work, awesome. If not, just keep authorizing shares and pulling in that salary. It's perfectly legal to benefit from us investors thinking his hand is stronger than it is.
If you don't laugh, you have to cry, after 7+ years in this stock.
That which is dead may never die.
My body is ready. Let my post-COVID $0.08's be green soon.
Long live INVC! Oh wait...they dead too.
Long live Innovation Laser Holding Company!
People: "We want the cure for COVID."
Leo: "Best I can do is swish/spit and half a laser."
The Squalus funding came from the money raised during the COVID hype. We didn't raise enough to advance the pipeline so he's placed a bet on an external company.
We're running a family office now.
We had our shot at COVID and blew it. I don't think anyone will run Brilacidin again in the clinic for any viral indication.
B-OM and Sqaulus Lasers are our holdings right now.
Doesn't mean much to us. Leo doesn't pay to play so he doesn't get any government cheddar.
COVID.
COVID hypetrain brought in a ton of money that the company could not otherwise have raised. Remember our share price was $0.06 with like $700K cash and $7M in liabilities in early 2020. We raised money during COVID 5-10x more efficiently than if we tried to do it with just B-OM - truthfully we wouldn't have been able to raise $10M...pre-COVID IPIX essentially failed.
Now we have some cash padding. Not enough to run a trial but several years worth of salaries at least.
Also, COVID screwed with many clinical trials even if we had the money.
Well I suppose multiple deals that are much more lucrative then the two we have already signed could get us there.
Standing by for the wealth effect.
It wasn't free. Most of us payers on the board have paid dearly.
I would venture to guess there isn't a single buy-and-hold investor who purchased shares of CTIX that isn't deep, deep in the red
Yeah but IPIX isn't worth $0.50/share. It has spent over a hundred trading sessions since our last major trial result under $0.05. All data about the company has had plenty of time to be digested and price discovery has found a rough range that is <10% of the number you cite.
What is the catalyst that will jump us 10x and then what is the catalyst that gets us a buyout for 12x (the third all time record premium for a pharma buyout)?
I'm not saying it can't happen, I'm just curious what two decisive events you think are going to cause these massive revaluations.
Why? Have we started lobbying for that cash?
How many non-lobbying companies have received any COVID money thus far? Last I checked it was 2ish.
Could have sent $4M in campaign donations but instead we bought some Squalus.
Yes.
$50M upfront + $200M milestones + 8% royalty = $0.70/share.
I expect the deal to look more like $5M-10M upfront + $70M milestones + 8% royalty with all development, sales, and manufacturing costs covered by the partner.
You have to keep in mind we have no leverage and virtually no ability to go it alone. $50M+ upfront is probably fantasy.
Why would anyone pay 150x for a company?
All time highest pharma buyouts were 26x, 17x, and 6x.
You really think you've found the golden nugget that is 6x more valuable by buyout premium than the all time GOAT?
That should tell you something.
B doesn't die.
If only it killed COVID as well as it kills companies.
Well there's always a large number of interested potential partners. Probably a dozen pharma companies would partner rights to B-OM for $1M upfront and a 2% royalty.
The question is how many are providing offers which are preferable to doubling the authorized shares and cranking the outstanding shares to 1 billion in order to run the phase 3 ourselves?
SAEs 5/30 placebo, 8/29 Brilacidin
Remove the ones which clearly have nothing to do with B-OM - things we didn't see in hundreds of patients in the ABSSSI/COVID trials:
1 Catheter site cellulitis
1 Hyperglycmia
1 Hypocglycaemia
Those don't sound related to Brilacidin and occurred in one patient each. Cutting those out its 5/30 vs 5/29. I dare say I'd rather have the nurse manage my Jello intake to keep the blood sugar where it needs to be than have extra days of SOM.
The PK data for all trials in the digestive tract have shown virtually no systemic absorption. Serum levels were orders of magnitude below what was dosed in the ABSSSI and COVID trials.
I was factoring that in. Going from no partner/phase3 start to market sales in 30 months is extremely aggressive even with fast track.
Our dreams were pretty wild back in 2015.
You thinking more than $800/share?
I also think B-OM would combo well with any IV treatment such as Galera's drug. Given the lack absorption of B there are very few safety and contraindication concerns from B-OM.
If we didn't have such a muddy finish on that phase 2 trial I think we would already have had a partner and be in a phase 3 right now.
Well, we doubled the outstanding share count the past few years to raise $20M-25M for COVID trials and other stuff?
If Leo sold half the company (all of B and K) for $25M, why would someone else offer $100M upfront for the remaining half? Additionally, our stock price, market cap, and pipeline are all lower/weaker than they were in mid 2020.
We can keep our fingers crossed...but based on the terms of the two deals we have signed and the fund raising choices the past few years, I'm not seeing much reason to believe we will be entertaining deals with $100M upfront payments any time soon.